ASX - By Stock
|
ACW |
Re:
Ann: ACW June 2024 quarterly activity report & Appendix 4C
|
|
stormer
|
62 |
16K |
3 |
19/08/24 |
19/08/24 |
ASX - By Stock
|
62
|
16K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW June 2024 quarterly activity report & Appendix 4C
|
|
stormer
|
62 |
16K |
0 |
19/08/24 |
19/08/24 |
ASX - By Stock
|
62
|
16K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW June 2024 quarterly activity report & Appendix 4C
|
|
stormer
|
62 |
16K |
1 |
19/08/24 |
19/08/24 |
ASX - By Stock
|
62
|
16K
|
1
|
|
ASX - By Stock
|
VSR |
Re:
Ann: M Walshe appointed as NED and resigned as CEO
|
|
stormer
|
32 |
7.0K |
2 |
16/08/24 |
16/08/24 |
ASX - By Stock
|
32
|
7.0K
|
2
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Extension of Entitlement Offer Closing Date to 04 Sept 2024
|
|
stormer
|
76 |
13K |
0 |
16/08/24 |
16/08/24 |
ASX - By Stock
|
76
|
13K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: M Walshe appointed as NED and resigned as CEO
|
|
stormer
|
32 |
7.0K |
3 |
15/08/24 |
15/08/24 |
ASX - By Stock
|
32
|
7.0K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
4 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
130
|
56K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
7 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
7
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
[INTERVIEW] Actinogen Medical reveals XanaCIDD phase 2a trials
|
|
stormer
|
47 |
13K |
1 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
47
|
13K
|
1
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Envu collaboration on Flavocide for mosquito management
|
|
stormer
|
22 |
4.1K |
2 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
22
|
4.1K
|
2
|
|
ASX - By Stock
|
BGT |
Re:
Ann: Envu collaboration on Flavocide for mosquito management
|
|
stormer
|
22 |
4.1K |
2 |
14/08/24 |
14/08/24 |
ASX - By Stock
|
22
|
4.1K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
3 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
130
|
56K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
3 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
130
|
56K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
6 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
130
|
56K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
3 |
13/08/24 |
13/08/24 |
ASX - By Stock
|
130
|
56K
|
3
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
6 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
8 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
8
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
0 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
1 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
9 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
9
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
0 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
2 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
2
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
4 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
4
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
1 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
1
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
6 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
6 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
6
|
|
ASX - By Stock
|
ACW |
Re:
Ann: ACW XanaCIDD phase 2a trial topline results
|
|
stormer
|
130 |
56K |
0 |
12/08/24 |
12/08/24 |
ASX - By Stock
|
130
|
56K
|
0
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
2 |
10/08/24 |
10/08/24 |
ASX - By Stock
|
119
|
26K
|
2
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
1 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
99
|
28K
|
1
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
0 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
99
|
28K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: M Walshe appointed as NED and resigned as CEO
|
|
stormer
|
32 |
7.0K |
0 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
32
|
7.0K
|
0
|
|
ASX - By Stock
|
VSR |
Re:
Ann: M Walshe appointed as NED and resigned as CEO
|
|
stormer
|
32 |
7.0K |
1 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
32
|
7.0K
|
1
|
|
ASX - By Stock
|
VSR |
Re:
Ann: M Walshe appointed as NED and resigned as CEO
|
|
stormer
|
32 |
7.0K |
2 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
32
|
7.0K
|
2
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
2 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
99
|
28K
|
2
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
0 |
09/08/24 |
09/08/24 |
ASX - By Stock
|
99
|
28K
|
0
|
|
ASX - By Stock
|
IIQ |
Re:
Ann: Quarterly Activities Report and Appendix 4C - June 2024
|
|
stormer
|
6 |
4.4K |
2 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
6
|
4.4K
|
2
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
0 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
0
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
0 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
99
|
28K
|
0
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
1 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
99
|
28K
|
1
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
1 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
1
|
|
ASX - By Stock
|
SPA |
Re:
Ann: Appendix 4C and Quarterly Activities Report
|
|
stormer
|
99 |
28K |
3 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
99
|
28K
|
3
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
2 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
2
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
0 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
0
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
1 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
1
|
|
ASX - By Stock
|
MHC |
Re:
Ann: Entitlement Offer to Raise up to $1.5 Million
|
|
stormer
|
119 |
26K |
0 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
119
|
26K
|
0
|
|
ASX - By Stock
|
ACW |
Re:
Ann: Trading Halt
|
|
stormer
|
76 |
34K |
12 |
08/08/24 |
08/08/24 |
ASX - By Stock
|
76
|
34K
|
12
|
|